Study of type II topoisomerase mutation in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa

Chinese Journal of Antibiotics

Volumn 28, Issue 3, 2003, Pages 155-159+171

  Li, Xue ru ^a   Jia, Wen xiang ^a   Yang, Chun ^a   Liu, Li ^a   Zeng, Wei ^a   Yang, Yuan ^a   Ma, Ju hui ^a   Zhang, Zai rong ^a   Cheng, Xi ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Drug resistance; Minimal inhibitory concentration (MIC); Pseudomonas aeruginosa; Type II topoisomerase gene mutation

Indexed keywords

CEFTAZIDIME; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); IMIPENEM; LEVOFLOXACIN; NORFLOXACIN; PIPERACILLIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; CODON; CORRELATION ANALYSIS; DNA SEQUENCE; DRUG ACTIVITY; DRUG SENSITIVITY; GENE AMPLIFICATION; GENE MUTATION; GENETIC CODE; GYRA GENE; GYRB GENE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PARC GENE; PARE GENE; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA;

EID: 0037261254     PISSN: 10018689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Wolfson J S, Hooper D C. Fluroquinolone antimicrobial agents [J]. Clin Microbiol Rev, 1989,2(3):378
2. Wang J C. DNA topoisomerase [J]. Ann Rev Biochem, 1996,65:635
3. Edlle J G, Barnard F M, Wentzell L M, et al. The interaction of drugs with DNA gyrase: a model for the molecular basis of quinolone action [J]. Nucleosides Nucleotides Nucleic Acids, 2000,19(8):1249
4. Ball P. Quinolone generation: natural history or natural selection? [J]. J Antimicrob Chemother, 2000, 46(Suppl 1,2): 17
5. Nakano M, Deguchi T, Kawamura T, et al. Mutations in gyrA and parC gene in fluroquinolone-resistant clinical isolates of P. aeruginosa [J]. Antimicrob Agents Chemother, 1997,41(10):2289
6. Li X R, Zu W, Jia W X, et al. Study on the gyrA mutations and the susceptibility to β-lactams in quinolone-resistant clinical isolates of Pseudomonas aeruginosa [J]. Chin J Antibiot, 2002,27(12):726
7. Kureishi A, Diver J M, Beckthold B, et al. Cloning and nucleotide sequence of P. aeruginosa gyrA gene from PAO1 and quinolone-resistant clinical isolates [J]. Antimicrob Agents Chemother, 1994,38(9):1944
8. Takashi T, Sakagawa E, Sugawara M. Detection of gyrA mutations among 335 Pseudomonas aeruginosa strains isolated in Japan and their susceptibilities to fluoroquinolones [J] Antimicrob Agents Chemother, 1999,43(2):406
9. Ouabdesselam S, Hooper D C, Tankovic J, et al. Detection of gyrA and gyrB mutations in quinolone-resistant clinical isolates of E. coli by single-strand conformational polymorphism analysis and determination of levels of resistance conferred by two different single gyrA mutations [J]. Antimicrob Agents Chemother, 1995,39(7):1667
10. National Committee for Clinical Laboratory Standards. Method for dilution antimicrobial susceptible test for bacteria that grow aerobically [S]. 4th ed. Approved Standard M7-A4 NCCLS, Vayne, Pa
11. Wretlind B. Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa [J]. Microb Drug Resist, 1998,4(3):257
12. Shen I I. Quinolone interactions with DNA and DNA gyrase [J]. Methods Mol Biol, 2001,95(2):171
13. Kohler T, Michea-Hamzehpour M, Plesiat P. Differential selection of multidrug efflux systems by quinolones in Pseudomonas aeruginosa [J]. Antimicrob Agents Chemother, 1997,41(11):2540
14. Pumbwe L, Piddock L J. Two efflux systems expressed simultaneously in multidrug-resistant P. aeruginosa [J]. Antimicrob Agents Chemother, 2000,44(12):2861